the aid library

LIST OPTIONS

Filter

9268

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (3085)

View PDF (4260)

Safety Monitoring of medicinal products

Uppsala Monitoring Centre World Health Organization (2012) C_WHO

Reporting system for the general public - This document aims to provide practical guidelines on how to set up national systems for consumers to report adverse reactions to medicines. The purpose is to help countries set up a well-organized and effective consumer reporting system within their pharmac... more

Download (485)

View PDF (350)

Global Antimicrobial Resistance Surveillance System (GLASS): Molecular methods

World Health Organization WHO (2019) C_WHO

Molecular methods for antimicrobial resistance (AMR)diagnostics to enhance the Global Antimicrobial Resistance Surveillance System

Download (396)

View PDF (986)

Treatment of tuberculosis - Annex 4 Evidence- to- decision tables

World Health Organization (2017) C_WHO

Guidelines for treatment of drug-susceptible tuberculosis and patient care Update 2017

Download (254)

View PDF (437)

Role of a medical review

World Health Organization (2012) C_WHO

Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?

Download (373)

View PDF (341)

Prendre soin des soignants

World Health Organisation (WHO) (2021) C_WHO

La santé est un droit humain universel et un facteur essentiel de bien-être, de développement économique, de croissance, de richesse et de prospérité pour tous. Les systèmes de santé jouent un rôle essentiel, car ils protègent, rétablissent et préservent la santé des patients et des p... more

Download (599)

View PDF (1040)

A people-centred model of TB care

World Health Organization Europe; Stop TB Partnership; ERS; et al. (2017) C_WHO

Blueprint for EECA countries, first edition

Download (464)

View PDF (691)

WHO policy on collaborative TB/HIV activities (Guidelines)

World Health Organization WHO (2012) C_WHO

Guidelines for national programmes and other stakeholders, for annexes see http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/

Download (457)

View PDF (458)

Supporting the routine use of evidence during the policy-making process: a WHO checklist

World Health Organisation (WHO) (2023) C_WHO

This checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health coverage (UHC). Its importance is emphasized in WH... more

Download (377)

View PDF (594)

Global Measles and Rubella Strategic Plan 2012-2020

World Health Organization WHO; Measles Initiative (2012) C_WHO

This ten year global plan for measles and rubella outlines the strategy that needs to be fully implemented to achieve the measles and rubella goals endorsed by the World Health Assembly. The plan sets out the: vision, goals and targets for the 2011-2020 period, recommended strategies, guiding princi... more

Download (337)

View PDF (410)

Service Delivery - Chapter 6

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Accessed: 26.02.2020

Download (652)

View PDF (902)

A people-centred model of TB care (Russian edition)

World Health Organization Europe; Stop TB Partnership; ERS; et al. Всемирная организация здравоохранения (2017) C_WHO

Blueprint for EECA countries, first edition МОДЕЛЬ ПРОТИВОТУБЕРКУЛЕЗНОЙ ПОМОЩИ, ОРИЕНТИРОВАННАЯ НА НУЖДЫ ЛЮДЕЙ Концептуальный проект модели для стран Восточной Европы и Центрально... more

Download (1040)

View PDF (644)

Self-Directed M&E Learning Workbook 1: An Orientation to District-Level Monitoring & Evaluation Duties

Ministry of Health & Ministry of Local Government, Gabarone, Botswana (2011) C2

District Level M & E Training and Reference Material for Primary Health Care Programmes

Download (1210)

View PDF (1506)

Zika: Strategic Response Framework & Joint Operations Plan January - June 2016
recommended

World Health Organization WHO (2016) C_WHO

The strategy focuses on mobilizing and coordinating partners, experts and resources to help countries enhance surveillance of the Zika virus and disorders that could be linked to it, improve vector control, effectively communicate risks, guidance and protection measures, provide medical care to thos... more

Download (261)

View PDF (573)

Operational handbook on tuberculosis: module 6: tuberculosis and co-morbidities, 3rd ed

World Health Organization WHO (2025) C_WHO

Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. This WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities aims to support countries in scaling up people-centred care, base... more

Download (275)

View PDF (523)

Coronavirus disease 2019 (‎COVID-19)‎ strategic preparedness and response plan: Accelerating readiness in the Eastern Mediterranean Region

World Health Organization WHO (2020) C_WHO

This document has been developed for the WHO Regional Office for the Eastern Mediterranean to establish a regional plan of action to support the countries of the Region to rapidly accelerate the scaling up of their capacities for the prevention and early detection of, and ... more

Download (447)

View PDF (714)

Water safety plan: a field guide to improving drinking-water safety in small communities

World Health Organization (WHO) (2014) C_WHO

This field guide is a practical tool for improving and maintaining drinking-water safety. It is designed to be used by YOU as a rural community member who shares responsibility for operation and management of the drinking-water supply in your community. It can also be used by YOU as a staff member o... more

Download (198)

View PDF (300)

Communicable and non-communicable diseases in Africa in 2021/22

World Health Organization Africa Region; WHO Africa World Health Organization Africa Region; WHO Africa (2023) C_WHO

This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tra... more

Download (627)

View PDF (348)

Management of critical COVID-19 Advanced non-invasive respiratory support: high-flow nasal oxygen and non-invasive ventilation -Part 3: NIPPV (CPAP and BiPAP)
recommended

World Health Organization WHO (2022) C_WHO

For patients on NIPPV or HFNO with persistent hypoxaemia or respiratory distress: • Check the equipment: inspect the exterior of the machine, the tubing (circuit), the mask for any sign of mechanical damage, confirm it fits securely without leak (if CPAP/BiPAP) and the filters are in place. Ensur... more

Download (259)

View PDF (234)

Operational handbook on tuberculosis: module 6: tuberculosis and comorbidities, 3rd ed

World Health Organization WHO (2025) C_WHO

Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. This WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities aims to support countries in scaling up people-centred care, ... more

Zika: Strategic Response Framework & Joint Operations Plan January - June 2016 recommended

Management of critical COVID-19 Advanced non-invasive respiratory support: high-flow nasal oxygen and non-invasive ventilation -Part 3: NIPPV (CPAP and BiPAP) recommended

Zika: Strategic Response Framework & Joint Operations Plan January - June 2016
recommended

Management of critical COVID-19 Advanced non-invasive respiratory support: high-flow nasal oxygen and non-invasive ventilation -Part 3: NIPPV (CPAP and BiPAP)
recommended